BIIB BIOGEN INC.

Price Chart

Executive Summary

Piper Sandler issued a double upgrade on NVDA from Neutral to Overweight on April 14, raising its price target to $214 from $177 (+21%). The call is contrarian: consensus is split 24 Buy / 18 Hold / 1 Sell, with a mean target of $217. Piper Sandler's new $214 target sits slightly below the $217 mean but above the $204.53 current price, implying ~5% upside. The firm has a strong 71% accuracy rate on 7 calls for NVDA, ranking among the top-tier covering firms. However, the broader analyst community has been cautious: EPS estimates for the current fiscal year have been revised down 13 times in the past 30 days vs. just 1 upward revision, and the current quarter saw 12 downward revisions. Momentum is mixed — 2 upgrades in the past 30 days (Piper Sandler, Wells Fargo, UBS) but no downgrades. Institutional flows show a large new position from Norges Bank ($464M) and FMR doubling its stake (+632%), while short interest sits at a high 65.8% of float, signaling heavy bearish positioning. No insider or congressional trades were recorded. The bottom line: Piper Sandler's double upgrade is a high-conviction contrarian call from a top-tier firm, but the heavy EPS revision headwinds and elevated short interest suggest near-term caution. Traders should watch for a catalyst — next earnings are July 29, over 3 months away — before committing capital.

Impact Score

Consensus & Targets

Consensus is 24 Buy (9 Strong Buy + 15 Buy), 18 Hold, 1 Sell. That's 56% Buy, 42% Hold, 2% Sell — a moderately bullish consensus but with a large hold contingent. Piper Sandler's Overweight aligns with the bullish camp but is a contrarian call given the recent EPS downgrade cycle.

Current price: $204.53. Mean target: $217.03 (implied upside +6.1%). Median target: $214 (implied upside +4.6%). High target: $275 (Guggenheim). Low target: $150. Piper Sandler's $214 is at the median, slightly below the mean — a relatively conservative bullish call. The target range is wide ($125 spread), reflecting high uncertainty.

Recent Analyst Activity

30-day analyst activity: 2 upgrades (Piper Sandler, Wells Fargo, UBS), 0 downgrades. However, EPS revisions are sharply negative: current fiscal year EPS estimates saw 13 downward revisions vs. 1 upward in the past 30 days; current quarter saw 12 downward vs. 0 upward. The next quarter (+1q) saw 8 downward vs. 3 upward. The trend is clearly negative on earnings expectations despite the bullish rating actions.

Firm Track Record — Piper Sandler

Piper Sandler accuracy: 54% on 3763 calls | avg return: 3.6%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

Piper Sandler has a 71% accuracy rate on 7 NVDA calls with an average return of 1.6%. This ranks as top-tier among covering firms. Best-performing firm: Jefferies (100% on 2 calls, +13% avg return). Worst-performing: Mizuho (33% on 3 calls, -5% avg return). Piper Sandler's accuracy is well above the average of ~50% for the broader analyst pool.

Earnings Estimates

Next earnings: Jul 29, 2026

Cross-Platform Signals

Insider trades: none recorded. Congressional trades: none. Institutional flows: bullish — Norges Bank opened a new $464M position, FMR doubled its stake (+632% to $1.66B). However, UBS trimmed (-32.3%) and Renaissance Technologies cut (-58.6%). Short interest is elevated at 65.8% of float, indicating heavy bearish positioning that could fuel a squeeze if positive catalysts emerge. The institutional buying and high short interest converge with the bullish analyst signal, but the EPS revision trend diverges negatively.

Documents Analyzed

Report based on filing metadata.

US Market Status